Markets:

Overview

News

Currencies

International

Treasuries

Eli Lilly (NY:LLY)

1,041.10 +22.23 (+2.18%)

Streaming Delayed Price Updated: 12:04 PM EDT, May 21, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Eli Lilly

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Eli Lilly's Next-Gen Obesity Drug Delivers Eye-Popping Weight Loss ↗

Today 9:15 EDT

Patients lost up to 85 pounds in a study of Eli Lilly's next-generation weight-loss drug, the company said Thursday.

Via Investor's Business Daily

Could Viking Therapeutics Be the Next Eli Lilly? ↗

Today 8:30 EDT

Demand for weight loss drugs may fuel growth for more than one player.

Via The Motley Fool

Eli Lilly & Co (NYSE:LLY) Proves a Smart Pick for a Rules-Based Dividend Growth Strategy ↗

Today 6:20 EDT

Via Chartmill

Medicine's Not Going Anywhere: 3 of the Most Resilient Healthcare ETFs ↗

Today 5:56 EDT

It's tough to think of an industry with more staying power than healthcare.

Via The Motley Fool

Topics ETFs Retirement

LLY: Eli Lilly & Co. Passes the Affordable Growth (GARP) Screen with Strong Momentum and Fair Valuation ↗

May 18, 2026

Via Chartmill

Best Weight Loss Drug Stocks to Buy in 2026 ↗

May 20, 2026

If you are looking for a GLP-1 investment, you can buy the leader, the underdog, or the upstart.

Via The Motley Fool

Topics Intellectual Property

Q1 Rundown: Elanco (NYSE:ELAN) Vs Other Pharmaceuticals Stocks

May 20, 2026

Looking back on pharmaceuticals stocks’ Q1 earnings, we examine this quarter’s best and worst performers, including Elanco (NYSE:ELAN) and its peers. The pha...

Via StockStory

Topics Artificial Intelligence Intellectual Property

From Zepbound to Foundayo: Lilly's Latest Results Support Oral GLP-1 Outlook ↗

May 20, 2026

Eli Lilly just got more good news, posting promising results for its oral GLP-1 as the firm looks to unlock new sources of demand.

Via MarketBeat

Trump's Stock Picks Perfectly Timed With New Medicare Rules: Report ↗

May 19, 2026

Donald Trump disclosed up to $680,000 in Eli Lilly stock purchases as Medicare initiatives advanced GLP-1 drug coverage.

Via Benzinga

Topics Government

Watch Out, Eli Lilly and Novo Nordisk: Viking Therapeutics' Pill Could Crash the Weight-Loss Party ↗

May 18, 2026

This dark horse in the weight loss drug race is worth keeping on your watch list.

Via The Motley Fool

Eli Lilly Stock: Next Stop $2,000? ↗

May 18, 2026

The company is riding an incredible tailwind.

Via The Motley Fool

Supreme Court Rejects Eli Lilly Appeal In Medicaid Fraud Case ↗

May 18, 2026

Supreme Court lets stand $194 million Medicaid fraud award against Eli Lilly in whistleblower case challenging False Claims Act.

Via Benzinga

Topics Fraud Whistleblower

3 Deeply Undervalued Stocks You Can Buy for Less Than $100 Right Now ↗

May 18, 2026

These stocks could look like steals in a few years.

Via The Motley Fool

Topics Intellectual Property

Could Eli Lilly's Next Weight Loss Drug Waylay Wegovy -- and Even Zap Zepbound? ↗

May 17, 2026

Promising clinical trial data suggests big opportunity with Eli Lilly's retatrutide GLP-1 candidate.

Via The Motley Fool

Is Kailera Therapeutics a Buy After Its Sizzling IPO? ↗

May 16, 2026

There's a new challenger to the more established players in the weight-loss drug space.

Via The Motley Fool

Topics Initial Public Offering

If You Invested $1000 In Eli Lilly Stock 20 Years Ago, You Would Have This Much Today ↗

May 15, 2026

Via Benzinga

Buy, Sell, or Hold Novo Nordisk at $46? ↗

May 15, 2026

Can Novo Nordisk thrive under intense competitive pressures?

Via The Motley Fool

My Top 3 Healthcare Stocks for May 2026 ↗

May 15, 2026

Healthcare is booming, and these three companies stand to profit handsomely from growing demand for medications and surgeries.

Via The Motley Fool

This Hot Weight-Loss Drug Stock May Have a Surprise Challenger

May 14, 2026

The race to dominate the weight-loss drug market is heating up, and investors should start watching this one smaller player closely.

Via Barchart.com

Topics Earnings Lawsuit

Should Eli Lilly Investors Worry About Its Newest Rival -- From Within? ↗

May 14, 2026

Eli Lilly is dominating one of the biggest growth markets in healthcare: the weight loss drug market.

Via The Motley Fool

Amphastar Pharmaceuticals Tackles BAQSIMI Discount Pressure, Keeps Sales Outlook ↗

May 14, 2026

Amphastar Pharmaceuticals (NASDAQ:AMPH) executives said the company is taking steps to address rebate and discounting pressure on BAQSIMI while maintaining its full-year revenue outlook, according to...

Via MarketBeat

This Weight-Loss Drug Challenger Could Follow Eli Lilly's Playbook: Analyst ↗

May 13, 2026

William Blair gives Kailera Therapeutics ($KLRA) an Outperform rating. Learn why analysts see a competitive edge in their GLP-1 assets.

Via Benzinga

Is Novo Nordisk's Rebound for Real--or Just a Head Fake? ↗

May 13, 2026

The worst might be in the rearview mirror.

Via The Motley Fool

Eli Lilly Says Newly Approved Foundayo, Lower-Dose Zepbound Help Sustain Weight Loss ↗

May 13, 2026

Eli Lilly data shows patients maintain weight loss with Foundayo or lower-dose Zepbound after switching from injectable therapies.

Via Benzinga

1 of Wall Street’s Favorite Stock to Target This Week and 2 We Avoid

May 13, 2026

The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f...

Via StockStory

Topics Retirement

Q1 Earnings Roundup: Amphastar Pharmaceuticals (NASDAQ:AMPH) And The Rest Of The Pharmaceuticals Segment

May 12, 2026

As the craze of earnings season draws to a close, here’s a look back at some of the most exciting (and some less so) results from Q1. Today, we are looking a...

Via StockStory

Topics Artificial Intelligence Intellectual Property

Eli Lilly (LLY) Stock Trades Up, Here Is Why

May 12, 2026

What Happened? Shares of global pharmaceutical company Eli Lilly (NYSE:LLY) jumped 2.4% in the afternoon session after the stock continued to rally as the co...

Via StockStory

Meet The New IPO Trying To Take On Eli Lilly And Novo Nordisk In Obesity ↗

May 12, 2026

Analysts initiated covered Tuesday of IPO stock, a potential competitor to Lilly and Novo in obesity.

Via Investor's Business Daily

Topics Initial Public Offering

Why Hims & Hers Health Stock Just Crashed ↗

May 12, 2026

Hims & Hers is unshaken by its earnings miss, with management promising even faster sales growth this year.

Via The Motley Fool

Topics Earnings Lawsuit

The 3 Best S&P 500 Stocks to Buy Now ↗

May 12, 2026

These growth stocks are benefiting from major tailwinds across cloud computing, digital payments, and healthcare.

Via The Motley Fool

Topics Artificial Intelligence Credit Cards Economy

< Previous 1 2 3 4 5 6 7 8 9

...

99 100 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.